Hologic, Inc. Share Price

Equities

HOLX

US4364401012

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 21:00:00 16/07/2024 BST 5-day change 1st Jan Change
78.46 USD +1.45% Intraday chart for Hologic, Inc. +4.96% +9.81%
Sales 2024 * 4.03B 309B Sales 2025 * 4.25B 326B Capitalization 18.31B 1,404B
Net income 2024 * 819M 62.81B Net income 2025 * 858M 65.81B EV / Sales 2024 * 4.6 x
Net Debt 2024 * 216M 16.56B Net cash position 2025 * 570M 43.7B EV / Sales 2025 * 4.18 x
P/E ratio 2024 *
22.8 x
P/E ratio 2025 *
21.6 x
Employees 6,990
Yield 2024 *
-
Yield 2025 *
-
Free-Float 77.04%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.45%
1 week+4.96%
Current month+5.67%
1 month+9.29%
3 months+4.46%
6 months+7.64%
Current year+9.81%
More quotes
1 week
75.82
Extreme 75.815
78.98
1 month
70.56
Extreme 70.56
78.98
Current year
70.53
Extreme 70.53
79.75
1 year
64.02
Extreme 64.02
82.45
3 years
59.78
Extreme 59.78
87.88
5 years
26.49
Extreme 26.49
87.88
10 years
22.70
Extreme 22.7
87.88
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 06/12/13
Director of Finance/CFO 54 31/12/05
Chief Operating Officer 44 31/08/17
Members of the board TitleAgeSince
Chief Executive Officer 60 06/12/13
Director/Board Member 69 14/05/17
Director/Board Member 63 30/11/16
More insiders
Date Price Change Volume
16/07/24 78.46 +1.45% 1,492,308
15/07/24 77.34 -0.45% 1,653,157
12/07/24 77.69 +1.57% 1,694,537
11/07/24 76.49 +0.95% 1,440,377
10/07/24 75.77 +1.36% 1,295,227

Delayed Quote Nasdaq, July 16, 2024 at 09:00 pm

More quotes
Hologic, Inc. is the world leader in the design, manufacturing and marketing of diagnostic products, medical imaging systems and surgical products dedicated to women's health. Net sales break down by area of application as follows: - molecular diagnostics (46.7%): rapid diagnostic tests for human diseases detection (sexually transmitted infections, respiratory diseases, viral diseases, infectious diseases, cancers of the cervix and prostate, etc.) and fetal fibronectin; - breast health (35.5%): digital mammography and breast biopsy solutions and systems; - gynecological surgery (15%): endometrial ablation devices, minimally invasive intervention systems for the hysteroscopic elimination of targeted intrauterine diseases (including fibroids and polyps). The group also offers fluid management systems for use in hysteroscopic procedures; - bone health (2.8%): bone imaging systems, bone sonometers and osteodensitometers for bone structure and density, and osteoporotic fractures risk assessment. Net sales break down by source of revenue between sales of products (81.4%) and services (18.6%). Net sales are distributed geographically as follows: the United States (75.9%), Europe (12.9%), Asia/Pacific (6.3%) and other (4.9%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
78.46 USD
Average target price
85.13 USD
Spread / Average Target
+8.51%
Consensus